Huang Qi, Tan Qi, Mao Kaimin, Yang Guanghai, Ma Guangzhou, Luo Ping, Wang Sufei, Mei Peiyuan, Wu Feng, Xu Juanjuan, Guo Mengfei, Lv Zhilei, Fan Jinshuo, Zhang Shuai, Wang Xuan, Jin Yang
Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, China.
Department of Cardiothoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, China.
Am J Cancer Res. 2018 Nov 1;8(11):2227-2237. eCollection 2018.
Adrenergic receptors (ARs), especially β-ARs, are constitutively expressed in most mammalian cells and are associated with various malignancies including lung cancer. Epidemiologic studies have reported that activation of β-AR signalling promotes the development and progression of lung cancer and that pharmacological interference by β-AR blockers could partially reverse lung cancer progression. In this review, we mainly focus on the role of β-ARs in lung cancer and then reveal the possible application of AR blockers in anti-tumour therapy for lung cancer.
肾上腺素能受体(ARs),尤其是β-肾上腺素能受体(β-ARs),在大多数哺乳动物细胞中组成性表达,并与包括肺癌在内的各种恶性肿瘤相关。流行病学研究报告称,β-AR信号的激活促进肺癌的发生和发展,而β-AR阻滞剂的药理学干预可部分逆转肺癌进展。在本综述中,我们主要关注β-ARs在肺癌中的作用,然后揭示AR阻滞剂在肺癌抗肿瘤治疗中的可能应用。